Top

Published in:

01-08-2016 | Original Article

Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer

Authors: Min-Sun Jin, Hyebin Lee, In Ae Park, Yul Ri Chung, Seock-Ah Im, Kyung-Hun Lee, Hyeong-Gon Moon, Wonshik Han, Kyubo Kim, Tae-Yong Kim, Dong-Young Noh, Han Suk Ryu

Published in: Virchows Archiv | Issue 2/2016

Abstract

Dysregulated energy metabolism is one of the main mechanisms for uncontrolled growth in solid tumors. Hypoxia-inducible factor 1-alpha (HIF1α) is a transcription factor implicated in regulating several genes that are responsible for cell metabolism, including carbonic anhydrase IX (CAIX). The aim of this study is to determine the clinical significance of immunohistochemical metabolic alteration in early-stage triple negative breast cancer (TNBC) patients who received cyclophosphamide-based chemotherapy or radiotherapy and those with basal phenotype. Immunohistochemical staining for HIF1α and CAIX was performed to determine the correlation with clinicopathologic variables and survival outcome on tissue microarrays from 270 early-stage TNBC patients. In vitro experiments with multiple human TNBC cell lines, suppression of HIF1α by small interfering RNA (siRNA) significantly reduced CAIX protein expression in all cell lines. In multivariate analyses for different therapeutic modalities and basal phenotype, combined HIF1α and CAIX protein overexpression was significantly associated with disease-free survival in the total cohort (OR = 2.583, P = 0.002), stratified cohorts expressing basal phenotype (OR = 2.234, P = 0.021), and in those patients who received adjuvant chemotherapy (OR = 3.078, P = 0.023) and adjuvant radiotherapy (OR = 2.111, P = 0.050), respectively. In early TNBC, combined HIF1α and CAIX protein expression may serve as an unfavorable prognostic indicator particularly in patients treated with cyclophosphamide-based chemotherapy or radiotherapy as well as those with basal phenotype of breast cancer.

Available only for authorised users

Rowell NP (2009) Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: a systematic review. Radiother Oncol 91(1):23–32. doi:10.1016/j.radonc.2008.09.026 CrossRefPubMed

Griffiths CL, Olin JL (2012) Triple negative breast cancer: a brief review of its characteristics and treatment options. J Pharm Pract 25(3):319–323. doi:10.1177/0897190012442062 CrossRefPubMed

Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8(3):235–244. doi:10.1016/s1470-2045(07)70074-8 CrossRefPubMed

Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8(6):519–530CrossRefPubMedPubMedCentral

Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8(9):705–713. doi:10.1038/nrc2468 CrossRefPubMed

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732. doi:10.1038/nrc1187 CrossRefPubMed

Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zat’ovicova M, Liao S, Portetelle D, Stanbridge EJ, et al. (1994) Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9(10):2877–2888PubMed

Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60(24):7075–7083PubMed

Choi J, Jung WH, Koo JS (2013) Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology 80(1):41–52. doi:10.1159/000339513 CrossRefPubMed

10.

Deb S, Johansson I, Byrne D, Nilsson C, Investigators K, Constable L, Fjallskog ML, Dobrovic A, Hedenfalk I, Fox SB (2014) Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. Mod Pathol 27(9):1223–1230. doi:10.1038/modpathol.2013.231 CrossRefPubMed

11.

Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, O’Toole SA, McNeil CM, Crea P, Segara D, Sutherland RL, Harris AL, Fox SB (2009) The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 100(2):405–411. doi:10.1038/sj.bjc.6604844 CrossRefPubMedPubMedCentral

12.

Chen CL, Chu JS, Su WC, Huang SC, Lee WY (2010) Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch 457(1):53–61. doi:10.1007/s00428-010-0938-0 CrossRefPubMed

13.

Eom KY, Jang MH, Park SY, Kang EY, Kim SW, Kim JH, Kim JS, Kim IA (2015) The expression of carbonic anhydrase (CA) IX/XII and lymph node metastasis in early breast cancer. Cancer Res Treat. doi:10.4143/crt.2014.243

14.

Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19(16):3660–3668PubMed

15.

Aomatsu N, Yashiro M, Kashiwagi S, Kawajiri H, Takashima T, Ohsawa M, Wakasa K, Hirakawa K (2014) Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline. BMC Cancer 14:400. doi:10.1186/1471-2407-14-400 CrossRefPubMedPubMedCentral

16.

Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Ryden L, Gallagher WM, O’Brien SL (2006) CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12(21):6421–6431. doi:10.1158/1078-0432.ccr-06-0480 CrossRefPubMed

17.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. doi:10.1093/annonc/mdr304 CrossRefPubMedPubMedCentral

18.

Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24(2):157–167. doi:10.1038/modpathol.2010.200 CrossRefPubMed

19.

Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41(3A):154–161CrossRefPubMed

20.

Span PN, Bussink J, Manders P, Beex LV, Sweep CG (2003) Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 89(2):271–276. doi:10.1038/sj.bjc.6601122 CrossRefPubMedPubMedCentral

21.

Meijer TW, Kaanders JH, Span PN, Bussink J (2012) Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 18(20):5585–5594. doi:10.1158/1078-0432.ccr-12-0858 CrossRefPubMed

22.

Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL (2003) Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 63(19):6130–6134PubMed

23.

Maseide K, Kandel RA, Bell RS, Catton CN, O’Sullivan B, Wunder JS, Pintilie M, Hedley D, Hill RP (2004) Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 10(13):4464–4471. doi:10.1158/1078-0432.ccr-03-0541 CrossRefPubMed

24.

Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB (2006) Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12(15):4562–4568. doi:10.1158/1078-0432.ccr-05-2690 CrossRefPubMed

25.

Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL (2006) Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer 13(3):921–930. doi:10.1677/erc.1.01216 CrossRefPubMed

26.

Overgaard J (2007) Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25(26):4066–4074. doi:10.1200/jco.2007.12.7878 CrossRefPubMed

27.

Koukourakis MI, Giatromanolaki A, Danielidis V, Sivridis E (2008) Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. Int J Radiat Biol 84(1):47–52. doi:10.1080/09553000701616114 CrossRefPubMed

28.

Dubois L, Peeters S, Lieuwes NG, Geusens N, Thiry A, Wigfield S, Carta F, McIntyre A, Scozzafava A, Dogne JM, Supuran CT, Harris AL, Masereel B, Lambin P (2011) Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 99(3):424–431. doi:10.1016/j.radonc.2011.05.045 CrossRefPubMed

29.

Yang JS, Lin CW, Chuang CY, Su SC, Lin SH, Yang SF (2015) Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma. Tumour Biol 36(12):9517–9524. doi:10.1007/s13277-015-3692-8 CrossRefPubMed

30.

Choi J, Kim d H, WH J, Koo JS (2013) Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res 15(5):R78. doi:10.1186/bcr3472 CrossRefPubMedPubMedCentral

31.

Jiang BH, Semenza GL, Bauer C, Marti HH (1996) Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Phys 271(4 Pt 1):C1172–C1180

32.

Rafajova M, Zatovicova M, Kettmann R, Pastorek J, Pastorekova S (2004) Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 24(4):995–1004PubMed

33.

Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J, Ratcliffe PJ, Cranston D, Harris AL (2002) The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 86(8):1276–1282. doi:10.1038/sj.bjc.6600215 CrossRefPubMedPubMedCentral

Title: Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer
Authors: Min-Sun Jin
Hyebin Lee
In Ae Park
Yul Ri Chung
Seock-Ah Im
Kyung-Hun Lee
Hyeong-Gon Moon
Wonshik Han
Kyubo Kim
Tae-Yong Kim
Dong-Young Noh
Han Suk Ryu
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 2/2016
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-016-1953-6

At a glance: The STEP trials

Springer Medicine

Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study

The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers

Epithelioid angiosarcoma of the thyroid gland without distant metastases at diagnosis: report of six cases with a long follow-up

Amplification of FGFR1 gene and expression of FGFR1 protein is found in different histological types of lung carcinoma

Molecular pathological classification of colorectal cancer

Peritoneal dissemination in early gastric cancer: importance of the lymphatic route